KTTA
Pasithea Therapeutics Corp
$
0.718
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7195
Open
0.681
VWAP
0.70
Vol
105.74K
Mkt Cap
5.34M
Low
0.681
Amount
74.25K
EV/EBITDA(TTM)
--
Total Shares
1.04M
EV
-130.77K
EV/OCF(TTM)
--
P/S(TTM)
--
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-3.800
-0.37%
Estimates Revision
Stock Price
Go Down
-16.51%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Pasithea Therapeutics Corp (KTTA.O) is -0.05, compared to its 5-year average forward P/E of -4.90. For a more detailed relative valuation and DCF analysis to assess Pasithea Therapeutics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.90
Current PE
-0.05
Overvalued PE
5.78
Undervalued PE
-15.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.76
Current EV/EBITDA
0.03
Overvalued EV/EBITDA
6.84
Undervalued EV/EBITDA
-8.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
11.49
Current PS
0.00
Overvalued PS
55.18
Undervalued PS
-32.21
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-8.92%
-3.68M
Operating Profit
FY2025Q1
YoY :
-7.71%
-3.56M
Net Income after Tax
FY2025Q1
YoY :
-56.49%
-1.61
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
792.0
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
792.0
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KTTA News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
07:15:04
Pasithea completes enrollment, initial dosing from Phase 1/1b trial of PAS-004
2025-06-11 (ET)
2025-06-11
07:16:36
Pasithea Therapeutics appoints Lee to its SAB
2025-06-02 (ET)
2025-06-02
08:30:21
Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study
Sign Up For More Events
Sign Up For More Events
News
9.0
07-31NewsfilterPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
5.0
06-11NewsfilterPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
9.0
05-20NewsfilterPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
Sign Up For More News
People Also Watch
CNET
ZW Data Action Technologies Inc
1.320
USD
-1.49%
AQB
AquaBounty Technologies Inc
0.770
USD
+4.05%
SHPH
Shuttle Pharmaceuticals Holdings Inc
3.540
USD
-1.39%
QLGN
Qualigen Therapeutics Inc
1.670
USD
-0.60%
BQ
Boqii Holding Ltd
2.580
USD
+4.88%
AZTR
Azitra Inc
0.153
USD
+4.08%
ICON
Icon Energy Corp
2.240
USD
+5.16%
SCNI
Scinai Immunotherapeutics Ltd
1.680
USD
+17.48%
FAQ
What is Pasithea Therapeutics Corp (KTTA) stock price today?
The current price of KTTA is 0.718 USD — it has increased 2.57 % in the last trading day.
What is Pasithea Therapeutics Corp (KTTA)'s business?
What is the price predicton of KTTA Stock?
What is Pasithea Therapeutics Corp (KTTA)'s revenue for the last quarter?
What is Pasithea Therapeutics Corp (KTTA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Pasithea Therapeutics Corp (KTTA)'s fundamentals?
How many employees does Pasithea Therapeutics Corp (KTTA). have?